AR110979A1 - Moléculas de unión a cd70 y métodos de uso de las mismas - Google Patents

Moléculas de unión a cd70 y métodos de uso de las mismas

Info

Publication number
AR110979A1
AR110979A1 ARP180100350A ARP180100350A AR110979A1 AR 110979 A1 AR110979 A1 AR 110979A1 AR P180100350 A ARP180100350 A AR P180100350A AR P180100350 A ARP180100350 A AR P180100350A AR 110979 A1 AR110979 A1 AR 110979A1
Authority
AR
Argentina
Prior art keywords
seq
cdr
amino acid
acid sequence
chain variable
Prior art date
Application number
ARP180100350A
Other languages
English (en)
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of AR110979A1 publication Critical patent/AR110979A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Reivindicación 1: Un polinucleótido aislado que codifica un receptor de antígeno quimérico (CAR) o receptor de célula T (TCR) que comprende una molécula de unión a antígeno que se une específicamente a CD70, en donde la molécula de unión a antígeno comprende: (a) una región determinante de complementariedad (CDR) 1 de región variable de cadena pesada (VH) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por GFTFSSY (SEQ ID Nº 71), GDSIISGGY (SEQ ID Nº 73) y GYTFTSY (SEQ ID Nº 75); (b) una región determinante de complementariedad (CDR) 2 de región variable de cadena pesada (VH) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por WYDGSN (SEQ ID Nº 72), FYSGS (SEQ ID Nº 74) y DPSGGS (SEQ ID Nº 76); (c) una región determinante de complementariedad (CDR) 3 de región variable de cadena pesada (VH) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por DLLRGVKGYAMDV (SEQ ID Nº 64), SGYSYALFDH (SEQ ID Nº 67) y DYGDYVFDY (SEQ ID Nº 76); (d) una región determinante de complementariedad (CDR) 1 de región variable de cadena ligera (VL) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por RASQSLRRIYLA (SEQ ID Nº 53), RASQFIGRYFN (SEQ ID Nº 56) y SGSSSNIGTNTVN (SEQ ID Nº 59); (e) una región determinante de complementariedad (CDR) 2 de región variable de cadena ligera (VL) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por DVFDRAT (SEQ ID Nº 54), AESSLQS (SEQ ID Nº 57) e INNQRPS (SEQ lD Nº 60); (f) una región determinante de complementariedad (CDR) 3 de región variable de cadena ligera (VL) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por QQYSDSPFT (SEQ ID Nº 55), QQSYSTPFT (SEQ ID Nº 58) y ATWDDSLNGPW (SEQ ID Nº 61). Reivindicación 60: Un vector que comprende el polinucleótido de cualquiera de las reivindicaciones 1 a 59. Reivindicación 63: Una célula que comprende el polinucleótido de cualquiera de las reivindicaciones 1 a 59, el vector de la reivindicación 60 ó 61, el CAR o TCR de la reivindicación 62, o cualquier combinación de estos. Reivindicación 68: Una composición que comprende el polinucleótido de cualquiera de las reivindicaciones 1 a 59, el vector de la reivindicación 60 ó 61, el CAR o TCR de la reivindicación 62, o la célula de cualquiera de las reivindicaciones 63 a 67. Reivindicación 73: Un método para tratar un cáncer en un sujeto que lo necesita, que comprende administrar al sujeto el polinucleótido de cualquiera de las reivindicaciones 1 a 59, el vector de la reivindicación 60 ó 61, el CAR o TCR de la reivindicación 62, la célula de cualquiera de las reivindicaciones 65 a 67, o la composición de la reivindicación 68 ó 69.
ARP180100350A 2017-02-14 2018-02-14 Moléculas de unión a cd70 y métodos de uso de las mismas AR110979A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762458879P 2017-02-14 2017-02-14

Publications (1)

Publication Number Publication Date
AR110979A1 true AR110979A1 (es) 2019-05-22

Family

ID=61283393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100350A AR110979A1 (es) 2017-02-14 2018-02-14 Moléculas de unión a cd70 y métodos de uso de las mismas

Country Status (7)

Country Link
US (2) US11046775B2 (es)
EP (2) EP3583129B1 (es)
AR (1) AR110979A1 (es)
ES (1) ES2900233T3 (es)
PT (1) PT3583129T (es)
TW (3) TWI785009B (es)
WO (1) WO2018152181A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
AU2019216420A1 (en) * 2018-02-01 2020-08-20 Pfizer Inc. Chimeric antigen receptors targeting CD70
SG11202011541SA (en) 2018-06-01 2020-12-30 Kite Pharma Inc Chimeric antigen receptor t cell therapy
CN110818802B (zh) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 一种嵌合t细胞受体star及其应用
CN109880802B (zh) * 2018-11-30 2022-12-13 北京美康基免生物科技有限公司 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
US20220047634A1 (en) * 2018-11-30 2022-02-17 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
US20220411478A1 (en) * 2019-09-16 2022-12-29 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022116952A1 (zh) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 靶向cd70的抗原结合蛋白及其应用
EP4263590A1 (en) 2020-12-21 2023-10-25 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4284918A1 (en) 2021-01-29 2023-12-06 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
CN116023490B (zh) * 2021-10-25 2023-08-25 重庆精准生物技术有限公司 靶向cd70的抗原结合片段和单链抗体及其应用
CN116023500B (zh) * 2021-10-25 2023-07-04 重庆精准生物技术有限公司 一种靶向全人源化cd70的嵌合抗原受体及其应用
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ATE373078T1 (de) 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
EA027900B1 (ru) * 2011-09-22 2017-09-29 Эмджен Инк. Связывающие антиген cd27l белки
US9422351B2 (en) * 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
TW201609812A (zh) * 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體

Also Published As

Publication number Publication date
TW202344517A (zh) 2023-11-16
TWI785009B (zh) 2022-12-01
TW202321305A (zh) 2023-06-01
WO2018152181A1 (en) 2018-08-23
US20180230224A1 (en) 2018-08-16
EP4008728A1 (en) 2022-06-08
ES2900233T3 (es) 2022-03-16
EP3583129A1 (en) 2019-12-25
TWI814525B (zh) 2023-09-01
US11046775B2 (en) 2021-06-29
TW201833326A (zh) 2018-09-16
PT3583129T (pt) 2021-12-14
EP3583129B1 (en) 2021-11-03
US20210277132A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
AR110979A1 (es) Moléculas de unión a cd70 y métodos de uso de las mismas
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR117727A1 (es) Anticuerpos que se unen a cd3
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
AR106365A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
AR102732A1 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
AR109450A1 (es) Moléculas de unión a ilt7 y métodos de uso de las mismas
PH12021550244A1 (en) Anti-btla antibody
PE20191404A1 (es) Proteinas de union al receptor de glucagon y metodos para usarlas
WO2019066435A3 (ko) Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
AR109857A1 (es) Anticuerpos anti-chikv y usos de éstos

Legal Events

Date Code Title Description
FB Suspension of granting procedure